These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37309115)

  • 21. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
    Santi Laurini G; Montanaro N; Motola D
    Eur J Clin Pharmacol; 2023 May; 79(5):657-661. PubMed ID: 36961579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
    Duijster JW; Lieber T; Pacelli S; Van Balveren L; Ruijs LS; Raethke M; Kant A; Van Hunsel F
    Front Immunol; 2023; 14():1078736. PubMed ID: 36793715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching hospital.
    Vigezzi GP; Lume A; Minerva M; Nizzero P; Biancardi A; Gianfredi V; Odone A; Signorelli C; Moro M
    Acta Biomed; 2021 Oct; 92(S6):e2021450. PubMed ID: 34739472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
    Oosterhuis I; Scholl J; van Puijenbroek E; Kant A; van Hunsel F
    Drug Saf; 2023 Jan; 46(1):65-75. PubMed ID: 36350465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.
    Mahroum N; Lavine N; Ohayon A; Seida R; Alwani A; Alrais M; Zoubi M; Bragazzi NL
    Front Immunol; 2022; 13():872683. PubMed ID: 35865539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.
    Amdany H; Koech B
    JBI Evid Implement; 2023 Jun; 21(2):146-155. PubMed ID: 36545897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy).
    Stefanizzi P; Ferorelli D; Scazzi FL; Di Lorenzo A; Martinelli A; Trinchera C; Moscara L; Miniello E; Di Bona D; Tafuri S
    Front Immunol; 2023; 14():1074246. PubMed ID: 36923411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
    Sadarangani M; Soe P; Shulha HP; Valiquette L; Vanderkooi OG; Kellner JD; Muller MP; Top KA; Isenor JE; McGeer A; Irvine M; De Serres G; Marty K; Bettinger JA;
    Lancet Infect Dis; 2022 Nov; 22(11):1553-1564. PubMed ID: 35964614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand.
    Sirisuk W; Limvorapitak W; Lolekha P; Methaset K; Kulkantrakorn K
    Clin Neurol Neurosurg; 2023 Aug; 231():107804. PubMed ID: 37295197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
    Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
    J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Ogar CK; Quick J; Gilbert HN; Vreman RA; Mantel-Teeuwisse AK; Mugunga JC
    Drug Saf; 2023 Apr; 46(4):357-370. PubMed ID: 36811813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors.
    Yoon D; Jeon HL; Noh Y; Choe YJ; Choe SA; Jung J; Shin JY
    J Korean Med Sci; 2023 Jun; 38(22):e170. PubMed ID: 37272559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
    Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
    JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees.
    Attia S; Mausbach K; Klugar M; Howaldt HP; Riad A
    Front Public Health; 2022; 10():846861. PubMed ID: 35462827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
    Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
    JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.